Retrophin

RTRX NASDAQ
21.46
+0.07
+0.33%
Opening 10:46 07/19 EDT
Open
21.40
Prev Close
21.39
High
21.77
Low
21.23
Volume
170.74K
Avg Vol (3M)
426.35K
52 Week High
33.00
52 Week Low
17.53
% Turnover
0.41%
Market Cap
889.29M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Retrophin RTRX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
MORE >

Recently

Name
Price
%Change